HAS-BLED
By Timo Strid
HAS-BLED is a medical utility designed to calculate the one-year risk of major bleeding for patients on warfarin therapy for atrial fibrillation. Based on clinical research published in Chest, the app provides a streamlined interface for rapid risk assessment. It is notable for its single-page design that updates risk scores in real-time as clinical variables are selected.
Overview · Full Intel report in progress
The App DNA
What makes this app unique?
For Healthcare professionals managing patients with atrial fibrillation who require bleeding risk stratification.
What does it look like?
Key features
Estimates the one-year risk of major bleeding for patients undergoing warfarin treatment.
Allows users to input all clinical selections on one screen for improved workflow efficiency.
Provides real-time updates to the risk score and assessment as clinical options are toggled.
How much does it cost?
Velocity
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for HAS-BLED
How's the Medical market?
The rivals identified
By University of Maryland Baltimore Foundation, Inc.
Both applications target healthcare professionals managing anticoagulation therapy for patients with atrial fibrillation. They compete directly for the same clinical workflow utility.
- HAS-BLED provides a dedicated calculator for the HAS-BLED score, while ATRIUM covers broader anticoagulation management.
- HAS-BLED features a single-page interface for real-time score updates, whereas ATRIUM lacks specific UI feature details.
Unlock the head-to-head verdict: where this rival wins, and where it loses.
Access the full report for freeThe Analyst's Read
Key takeaways for HAS-BLED
Where is it heading?
Bottom line
This app serves as a specialized clinical tool for calculating HAS-BLED scores based on established medical literature.
Report last updated